
    
      The study includes an antiviral treatment with interferon-free regimen followed by lymphoma
      restaging; following the end of antiviral treatment patients will be evaluated for sustained
      virological response and safety parameters every 3 months for 1 year and then every 6 months
      for 2 years. ORR and vital status will be also evaluated.
    
  